Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGLU: IL-6 and Glucagon Interplay
NCT06721910Completed
- Sponsor
- University Hospital Basel
- Start
- Jan 2025
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Randomised, double-blind trial of tocilizumab in Glucagon resistance (2 arms), sponsored by University Hospital Basel. Primary endpoint: Change in maximum glucagon-induced reduction in total plasma amino acid concentrations. Started Jan 2025; status: completed.
02
Drugs
tocilizumab
03
Conditions
Glucagon resistance
Beyond the preview
Go deeper on NCT06721910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721910.